ALK and lung carcinoma: However, in the future, 10% of patients with non-smoking NSCLC should be included in different molecular studies, which will show that NSCLC’s origin is more significant than the already known oncogenic drivers of lung cancer, such as EGFR, ALK, or ROS1 [30].